Tarsus Pharmaceuticals

Update in progress

TARS (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Tarsus Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on eye-care medicines in the United States. Its lead product, XDEMVY, is a lotilaner ophthalmic solution for demodex blepharitis. It sells to specialty pharmacies, distributors, clinics, hospitals, and federal programs. It is developing TP-04 for ocular rosacea and TP-05 for Lyme prevention, plus lotilaner API work, with a China collaboration for TP-03. Based in Irvine, CA.

Company score

Sentiment: 0.38; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.29; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.09; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.11; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.24; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive